|
| Press Releases |
|
 |
|
| Monday, June 3, 2024 |
|
|
エーザイ、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向けたベンチャー投資事業を強化 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向け、革新的技術やサービスの発掘とそれを有するベンチャー企業の支援、将来的な提携を目的とし、2019 年に開始したベンチャー投資事業を強化し、継続することを決定しましたのでお知らせします。 more info >> |
|
| Tuesday, May 28, 2024 |
|
|
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD (early AD). more info >> |
|
| Thursday, May 23, 2024 |
|
|
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 |
| Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4. more info >> |
|
| Wednesday, May 22, 2024 |
|
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan |
| Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan. more info >> |
|
| Wednesday, May 15, 2024 |
|
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Monday, May 13, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
| Thursday, April 18, 2024 |
|
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
| Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
| Wednesday, April 17, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
| Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. more info >> |
|
|
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は本日、日本において自社創製の抗てんかん剤「フィコンパ(R)」（一般名：ペランパネル水和物、海外製品名：「Fycompa(R)」)の点滴静注用製剤について新発売したことをお知らせします。 more info >> |
|
| Wednesday, April 3, 2024 |
|
|
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
| Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX"). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Baguio Wins Two Contracts for Smart Food Waste Recycling Machines and Smart Balances from EPD
Jan 20, 2025 21:20 HKT/SGT
|
|
|
碧瑶赢得环保署智能厨余回收机及智能磅两份合约
Jan 20, 2025 21:12 HKT/SGT
|
|
|
碧瑤贏得環保署智能廚餘回收機及智能磅兩份合約
Jan 20, 2025 20:41 HKT/SGT
|
|
|
DENSO Exhibits at Bharat Mobility Global Expo 2025, New Delhi
Jan 20, 2025 20:26 JST
|
|
|
Transforming Philippine Healthcare: The 2025 Philippine Hospital & Healthcare Digitalization Summit
Jan 20, 2025 16:59 HKT/SGT
|
|
|
Q2 Metals Announces Details of its Expansion Drill Program for the Cisco Lithium Project in Eeyou Istchee James Bay, Quebec
Jan 20, 2025 16:05 HKT/SGT
|
|
|
Celebrate Chinese New Year with Vibrant Festivities at Spritzer EcoPark
Jan 20, 2025 15:30 HKT/SGT
|
|
|
三菱重工、人事異動を発表
Jan 20, 2025 15:30: JST
|
|
|
Hitachi Acquires a Sales and Maintenance Service Company for Large Motors in the United States
Jan 20, 2025 15:07 JST
|
|
|
三菱造船とTPFC、タブレット端末を利用したポータブル運航支援システム「ナビン」のリース販売を開始
Jan 20, 2025 14:00: JST
|
|
|
Suzuki's First BEV "e VITARA" Adopts eAxle
Jan 20, 2025 13:58 JST
|
|
|
Honda、「FREED e:HEV｣を一部改良
Jan 20, 2025 11:20: JST
|
|
|
Green Rain Solar Inc.（現代公司 The Now Corporation (OTC:NWPN) 的子公司）宣布推出帶有整合灌溉和備用電力系統的自給式太陽能溫室
Jan 20, 2025 11:00 HKT/SGT
|
|
|
Hypertec Cloud 與 Potentia 合作推動可持續 AI 雲端擴展，在北美新增 480MW 的平衡容量
Jan 20, 2025 11:00 HKT/SGT
|
|
|
Honda Presents the World Premier of BF300 Large-size Outboard Motor at the Dusseldorf Boat Show 2025
Jan 20, 2025 11:36 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
